Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Bulks Up Biopharma With $400 Million CoGenesys Acquisition

Executive Summary

Teva Pharmaceuticals will acquire the privately held biopharma CoGenesys for $400 million in an effort to strengthen its biogenerics position, the company announced Jan. 22

You may also be interested in...



Merck’s Ambitious Plans For Follow-On Biologics

Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9

Merck’s Ambitious Plans For Follow-On Biologics

Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9

Teva R&D Spending Target Raised To 7.5% Of Sales

Teva Pharmaceuticals will boost research and development spending this year toward a new goal of 7.5 percent of sales, company executives announced during the firm's fourth quarter earnings call Feb. 12

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel